Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Tuberc Lung Dis. 2012 Dec;16(12):1566-73. doi: 10.5588/ijtld.12.0569.

A rational vaccine pipeline for tuberculosis.

Author information

1
Global Affairs, Aeras, Rockville, Maryland 20850, USA. mbrennan@aeras.org

Abstract

The development of tuberculosis (TB) vaccines is at a turning point, with the promise of new vaccines on the horizon. Over the next few years, it is possible that we will see a phase III multi-site clinical trial of at least one new TB vaccine and perhaps the introduction of a TB vaccine by the end of the decade. However, many gaps remain in our understanding of TB pathogenesis as well as the host immune responses required to provide protective immunity. A major challenge for TB vaccines is to establish a correlate of vaccine immunity which would greatly facilitate bridging studies needed to approve, license and distribute new TB vaccines in all areas endemic for TB. This will require TB vaccines that are both safe and effective in all populations. It cannot be accomplished without hard work as well as additional resources that match the ambitious goals of the TB community.

PMID:
23131253
DOI:
10.5588/ijtld.12.0569
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Ingenta plc
    Loading ...
    Support Center